[ad_1]
The world’s largest retailer is providing affordable insulin medications to millions of Americans with diabetes.
Wal-Mart announced on Tuesday that it will launch its first private-label analog insulin in its U.S. pharmacies-the world’s largest retailer said this move could help its millions of U.S. customers with diabetes cope with the soaring prices of prescription drugs.
Walmart said in a press release: “We know that many people with diabetes are struggling to cope with the financial burden of this situation, and we are focused on helping by providing affordable solutions.” “We also know that this situation will Disproportionately affect the underserved population.”
The retail giant’s private ReliOn NovoLog Insulin products include simulated insulin vials priced at $72.88 and FlexPen priced at $85.88.
Wal-Mart said these products will save customers up to 75% of the cash price of branded analog insulin products. This means “up to US$101 savings per brand vial or US$251 per brand FlexPens packaging”.
Wal-Mart said that these new products are produced in cooperation with the pharmaceutical company Novo Nordisk and are intended for use by patients with type 1 and type 2 diabetes.
Simulated or synthetic insulin is cultivated in the laboratory and changed to have special characteristics, such as acting faster or longer than human insulin.
ReliOn NovoLog is a fast-acting analog insulin used to control hyperglycemia in adults and children with diabetes. It will require a doctor’s prescription and will be available in Wal-Mart’s US pharmacies starting next week, and in Sam’s Club pharmacies from mid-July.
Nearly one in ten adults, or approximately 34 million Americans, has diabetes.
Most of them suffer from type 2 diabetes, which is a chronic disease related to genetics. Type 2 diabetes is also associated with weight gain and lack of exercise.
The right diet and exercise can help control type 2 diabetes. Although not all diabetics need insulin, it is a life-saving medicine and is essential for many people to maintain good health.
1.2 million people with type 1 diabetes, an autoimmune disease, need to use insulin for life after the pancreas stops producing enough insulin.
For a long time, high insulin prices have been criticized by patients, advocates and US lawmakers, which has led Congress to investigate the affordability and access of people who need insulin to control blood sugar levels.
“We know that many people with diabetes are struggling to cope with the financial burden of this disease, and we are focused on helping by providing affordable solutions. We also know that this situation will have a disproportionate impact on the underserved population. ,” Cheryl Pegus, executive vice president of Walmart Health and Wellness, said in a statement.
According to the American Diabetes Association, diabetes is accompanied by high medical costs, usually as high as US$9,601 per person per year.
Between 2007 and 2017, the total out-of-pocket expenses of people with Medicare Part D on insulin products soared from US$236 million to US$984 million. Caesars Family Foundation. Medicare Part D is a drug benefit that helps Medicare beneficiaries pay for self-administered prescription drugs through prescription drug insurance premiums.
For many years, Wal-Mart has been trying to stand at the forefront of retailers and provide customers with more affordable drug options. In 2006, it began selling generic drugs at a price of $4 per month. This move was later adopted by other pharmacies.
[ad_2]
Source link
